Skip to content

The Efficacy of a Tart Cherry Drink for the Treatment of Patellofemoral Pain in Recreational Athletes.

The Efficacy of a Tart Cherry Drink for Patellofemoral Pain.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03743519
Enrollment
24
Registered
2018-11-16
Start date
2019-05-30
Completion date
2020-06-01
Last updated
2020-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patellofemoral Pain

Brief summary

Patellofemoral pain (PFP) is the most common chronic pathology in sports medicine and physiotherapy clinics. As pain and inflammation are the main symptoms of PFP, non-steroidal anti-inflammatory and analgesic medications are often utilized to decrease pain and inflammation; however alternative treatments are increasingly being sought due to the cardiovascular and gastrointestinal side effects of traditional pain medications. Most researchers advocate conservative treatment, though there is still insufficient clarity regarding the effectiveness of conservative treatment modalities. Dietary interventions for PFP have not received any attention in clinical literature, yet there is a growing body of evidence indicating that cherries have significant anti-inflammatory, antioxidant and pain-mediating effects. Therefore, the primary purpose of the proposed investigation was to test (using a randomized control investigation) the ability of a tart cherry juice blend to provide symptom relief in recreational athletes with PFP and to understand the biological and mechanical mechanisms behind any changes in PFP symptoms.

Interventions

DIETARY_SUPPLEMENTCherry juice

30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.

DIETARY_SUPPLEMENTPlacebo

Identical in taste and colour to the Cherry juice, but with no anthocyanin content

Sponsors

University of Central Lancashire
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Recreationally active * Suffering from mild to moderate patellofemoral pain with no evidence of any other condition.

Exclusion criteria

* Rheumatoid arthritis or other systemic inflammatory condition * Chronic pain syndrome * Corticosteroid medication in last 2 months (intra-articular or oral) * Intra-articular injections of hyaluronic acid in the last 9 months * Pregnancy * Diabetes * Food allergies to cherries.

Design outcomes

Primary

MeasureTime frameDescription
Knee injury and Osteoarthritis Outcome Score (KOOS) - patellofemoral scale6-weeksThis is a questionnaire based measurement that allows participants to subjectively rate the extent of their patellofemoral pain symptoms. This measurement is scored on a 0-100 scale with 100 indicating no pain.

Secondary

MeasureTime frameDescription
Plasma urate6-weeks
Creatinine6-weeks
COOP-WONCA - psychological wellbeing6-weeksThis is a questionnaire based measurement that allows participants to subjectively rate their psychological wellbeing. This measurement provides a value that is an average score of 6 questions (overall health, daily activities, physical fitness, feelings, social activities and change in health) that range from 1-5. A lower score indicates better psychological wellbeing.
High sensitivity C-reactive protein6-weeks
Pittsburgh Sleep Quality Index6-weeksThe Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.
human TNF-alpha6-weeks

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026